Key Takeaways for AbbVie Stock as of July 2026
- Across-the-Board Beat: AbbVie stock enters August 2026 off a Q2 print that topped Street estimates on every headline line, with revenue of $16.99B beating the $16.76B estimate by 1.36% and adjusted EPS of $3.65 landing $0.06 above guidance midpoint.
- Guidance Squeeze: Management raised full-year revenue guidance by $300M to ~$67.6B and lifted adjusted EPS guidance to $13.87-$14.07, a range that folds in $0.14 of dilution from the pending Apogee Therapeutics deal against a $0.10 improvement in the underlying business.
- Immunology Surge: Skyrizi sales hit $5.5B, up 24% operationally, while Rinvoq crossed $2.5B, up 23.7%, pushing total immunology revenue to $8.8B and growth of 14.6% YoY.
- CFO’s Dilution Math: CFO Scott Reents said the Apogee acquisition financing “more than offsetting our underlying overperformance,” a line that reframes an otherwise clean beat quarter around near-term deal costs.
AbbVie’s Q2 Earnings Beat Everywhere, But Apogee Dilution Ate the Upgrade
AbbVie (ABBV) closed its second quarter of 2026 on June 30 with net revenues of nearly $17 billion, up 10.2% year over year and $300 million ahead of the company’s own expectations. Adjusted earnings per share came in at $3.65, six cents above the guidance midpoint the company had set entering the quarter. That beat arrived alongside a raised full-year outlook, the third such increase this year, taking cumulative 2026 revenue guidance up by $600 million since January.
The growth came from a narrow but powerful set of products. Skyrizi and Rinvoq, AbbVie’s two lead immunology drugs, both grew above 20% operationally, and the neuroscience portfolio matched that pace. Immunology revenue reached $8.8 billion for the quarter, up 14.6%, with Skyrizi alone contributing $5.5 billion. CEO Rob Michael credited the momentum to execution across “double-digit sales growth from our diverse portfolio,” but the diversity claim only stretches so far when three product lines are doing most of the work while Humira continues sliding, down 36.1% on biosimilar erosion.
That growth story ran into a financing story on the same call. AbbVie is financing its planned acquisition of Apogee Therapeutics, a deal adding dermatology and respiratory assets to the immunology pipeline, and the cost of that deal now shows up directly in guidance. CFO Scott Reents laid out the math plainly on the Q2 earnings call: “This update reflects a $0.10 improvement in the outlook of our existing business based on strong second quarter results and continued momentum. It also now includes $0.14 of anticipated dilution related to the planned Apogee acquisition that is more than offsetting our underlying overperformance.” In other words, the business got better, and the guide still went down relative to where the beat alone would have taken it.
Cash flow told a similar story of a quarter with real strength and real costs sitting side by side. Operating cash flow fell 33.3% year over year to $3.44 billion, missing the prior-quarter run rate, while net interest expense guidance for the full year rose $200 million to account for Apogee’s financing. Third-quarter guidance calls for revenue near $17.2 billion and adjusted EPS between $3.84 and $3.88, a range that already assumes a partial quarter of acquisition-related dilution before the deal even closes.
TIKR Values AbbVie Stock at $342, Pricing In Continued Immunology Growth
TIKR’s mid-case model values AbbVie at $342 by December 2030, implying a 40% total return from the current price of $244, or 8% annualized over the next 4.4 years.
That annualized return sits in the mid-single-to-high-single-digit range typical of large, slower-growing pharmaceutical names, positioning AbbVie stock as a steadier compounding story rather than a rapid re-rating candidate. The model’s low and high cases, spanning $326 to $473, bracket a wide range of outcomes tied mostly to how durable Skyrizi and Rinvoq’s growth proves over the model’s ten-year window.
The target is reachable because the exact growth drivers the model needs, Skyrizi and Rinvoq compounding above 20%, are already showing up in the reported numbers, and the raised full-year revenue guide confirms management sees no near-term slowdown. The Apogee dilution complicates the earnings path over the next few quarters, but it doesn’t change the underlying immunology trajectory the target depends on.
That’s not a new test for AbbVie stock either: shares already clawed back almost all of a 19% drawdown earlier this year, even after the market had priced in the Apogee dilution in full.
Should You Invest in AbbVie Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up AbbVie Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track AbbVie Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ABBV stock on TIKR for Free →
Looking for New Opportunities?
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
#Adessonews seleziona nella rete articoli di particolare interesse.
Se vuoi leggere l’articolo completo clicca sul seguente link
Gian Estrada
Source link
